Colquhounia Root Tablet as an immune-metabolic adjunct for residual kidney risk in heavy-proteinuric type 2 diabetic kidney disease: a propensity-score-matched real-world study
Main finding · MAKE incidenceResult — go to the resultAdjusted hazard ratio 0.60 95% CI 0.43–0.85Authors' conclusion
Adjunctive CRT was associated with improved kidney outcomes in high-risk heavy-proteinuric DKD
Study context
- Population
- Heavy-proteinuric T2D diabetic kidney disease (DKD) (UACR >300 mg/g) despite guideline-directed therapy (RAS blockade, SGLT2i, finerenone); matched cohort median UACR 1818 mg/g, 40.2% KDIGO very high risk159 matched pairs
- Participants
- 159 vs 159
- Exposure
- Adjunctive Colquhounia Root Tablet (CRT) vs no CRT
- CRTn = 159
- No CRTn = 159reference
- Outcome
- MAKE: ≥57% sustained eGFR decline, end-stage renal disease, or kidney-related death
- Follow-up
- 5 years
Methodological detailspropensity-score matched, hospital-based electronic health records, real-world
- Propensity-score matched
- Hospital-based electronic health records
- Real-world
Main finding
MAKE incidence
Adjusted hazard ratio
0.60
95% CI 0.43–0.85
P = 0.004
By group
CRTvs No CRT
aHR 0.60 (95% CI 0.43–0.85); P = 0.004
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | CRT | No CRT | P value |
|---|---|---|---|
| Annual eGFR declineSlower decline with CRT | −5.08 mL/min/1.73 m²/year | - 7.05 mL/min/1.73 m²/year | P < 0.001 |
| UACR change · 12 monthsGreater UACR reduction with CRT | −52.8% | 1.8% | P < 0.001 |
Safety
- Comparable safety
Original publication
Colquhounia Root Tablet as an immune-metabolic adjunct for residual kidney risk in heavy-proteinuric type 2 diabetic kidney disease: a propensity-score-matched real-world study. Diabetes Res Clin Pract. Published 25 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →